Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Work In Process (2016 - 2025)

Avanos Medical (AVNS) has disclosed Work In Process for 12 consecutive years, with $25.2 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 19.43% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, up 19.43% year-over-year, with the annual reading at $25.2 million for FY2025, 19.43% up from the prior year.
  • Work In Process hit $25.2 million in Q4 2025 for Avanos Medical, down from $29.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $34.8 million in Q3 2021 to a low of $19.8 million in Q4 2023.
  • Historically, Work In Process has averaged $27.9 million across 5 years, with a median of $27.2 million in 2024.
  • Biggest five-year swings in Work In Process: plummeted 31.7% in 2023 and later rose 26.29% in 2025.
  • Year by year, Work In Process stood at $33.2 million in 2021, then dropped by 28.31% to $23.8 million in 2022, then decreased by 16.81% to $19.8 million in 2023, then increased by 6.57% to $21.1 million in 2024, then increased by 19.43% to $25.2 million in 2025.
  • Business Quant data shows Work In Process for AVNS at $25.2 million in Q4 2025, $29.3 million in Q3 2025, and $28.5 million in Q2 2025.